Harrow Health, Inc. (HROW) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on July 18, 2023, by Harrow Health, Inc. The filing details significant corporate developments including the amendment of a credit facility, preliminary financial guidance for the second quarter of 2023, the announcement of a common stock offering, and the acquisition of commercial rights for two ophthalmic product portfolios.
Key Financial Metrics and Capital Structure
- Q2 2023 Guidance (Preliminary): Management expects total revenues of over $31,000,000 and Adjusted EBITDA of over $9,300,000 for the three months ended June 30, 2023.
- Debt Facility Update: The Oaktree Loan credit facility size was increased from $100,000,000 to $112,500,000.
- Loan Drawdowns: The Company plans to draw an additional $12,500,000 to fund acquisition payments and working capital. Following this draw, total principal drawn will be $77,500,000, with up to $35,000,000 remaining available upon commercialization of TRIESENCE.
- Acquisition Costs: Initial payments of $8,000,000 are required for the VEVYE Acquisition and $8,000,000 for the Santen Products Acquisition.
Material Changes and Strategic Acquisitions
The Company executed two major acquisitions on July 18, 2023:
- VEVYE Acquisition: Acquired U.S. and Canadian commercial rights to VEVYE (cyclosporine ophthalmic solution 0.1%), the first cyclosporine-based product for dry eye disease signs and symptoms. Consideration includes an $8,000,000 initial payment, low double-digit royalties, and potential milestones.
- Santen Products Acquisition: Acquired exclusive commercial rights to certain ophthalmic products (including Verkazia and Cationorm Plus) via agreements with Santen and Eyevance. Consideration includes an $8,000,000 initial payment, various manufacturing milestones, and royalties (low double-digit for Verkazia, high single-digit for Cationorm Plus). Santen will continue selling these products on the Company's behalf for approximately four months, transferring net profits to Harrow.
Guidance, Outlook, and Risks
Management provided preliminary, unaudited guidance for Q2 2023, noting that actual results may vary due to uncertainties in investment gains/losses, inventory reserves, and stock-based compensation. Final GAAP results are expected in early August 2023. The Company also announced a common stock offering to raise capital, with road show presentations scheduled. The filing includes standard forward-looking statement disclaimers regarding risks that could cause actual results to differ materially from expectations.
Investor Verification Checklist
- Verify the final audited Q2 2023 financial results when released in early August 2023 to confirm the preliminary revenue and Adjusted EBITDA estimates.
- Review the full text of the First Amendment to the Credit Agreement (Oaktree Amendment) for specific covenants and conditions attached to the $12.5 million loan increase.
- Confirm the closing status and regulatory approvals for the VEVYE and Santen Products Acquisitions.
- Monitor the terms and pricing of the announced common stock offering to assess potential dilution.
- Track the commercialization timeline for TRIESENCE, which is a condition for accessing the remaining $35 million of the credit facility.